p38β/MAPK11 + p38α/MAPK14 Antibody (Rabbit mAb) [M11B5]

CatNo: F9010

    Application: Reactivity:
    • Lane 1: Hela, Lane 2: 293T, Lane 3: Jurkat, Lane 4: K562
    1/

    当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    使用情報

    Dilution
    1:1000 - 1:10000
    1:100
    1:100 - 1:250
    Application
    WB, IHC, IF
    Source
    Rabbit Monoclonal Antibody
    Reactivity
    Mouse, Human
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW Observed MW
    41 kDa 124 kDa, 42 kDa
    *なぜ予測分子量と実際の分子量が異なるのか?
    下記の原因により、実際の分子量が予測と異なる:タンパク質の翻訳後修飾(リン酸化/糖鎖付加),スプライシングバリアント,イソフォーム,相対的な電荷,ポリマー。
    ポジティブコントロール Human skin carcinoma tissue; Recombinant Human p38 alpha/MAPK14 protein; Recombinant Human p38 beta/MAPK11 protein (His tag N-Terminus); HAP1 cells; HeLa cells; Jurkat cells; K562 cells; MCF-7 cells
    ネガティブコントロール Recombinant Human p38γ/MAPK12 protein (His tag N-Terminus); Recombinant Human p38δ/MAPK13 protein (His tag N-Terminus)

    プロトコール

    WB
    Experimental Protocol:
     
    Sample preparation
    1. Tissue: Lyse the tissue sample by adding an appropriate volume of ice-cold RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail),and homogenize the tissue at a low temperature or lyse it by sonication on ice, then incubate on ice for 30 minutes.
    2. Adherent cell: Aspirate the culture medium and wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    3. Suspension cell: Transfer the culture medium to a pre-cooled centrifuge tube. Centrifuge and aspirate the supernatant. Wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    4. Place the lysate into a pre-cooled microcentrifuge tube. Centrifuge at 4°C for 15 min. Collect the supernatant;
    5. Remove a small volume of lysate to determine the protein concentration;
    6. Combine the lysate with protein loading buffer. Boil 20 µL sample under 95-100°C for 5 min. Centrifuge for 5 min after cool down on ice.
     
    Electrophoretic separation
    1. According to the concentration of extracted protein, load appropriate amount of protein sample and marker onto SDS-PAGE gels for electrophoresis. Recommended separating gel (lower gel) concentration: 10%. Reference Table for Selecting SDS-PAGE Separation Gel Concentrations
    2. Power up 80V for 30 minutes. Then the power supply is adjusted (110 V~150 V), the Marker is observed, and the electrophoresis can be stopped when the indicator band of the predyed protein Marker where the protein is located is properly separated. (Note that the current should not be too large when electrophoresis, too large current (more than 150 mA) will cause the temperature to rise, affecting the result of running glue. If high currents cannot be avoided, an ice bath can be used to cool the bath.)
     
    Transfer membrane
    1. Take out the converter, soak the clip and consumables in the pre-cooled converter;
    2. Activate PVDF membrane with methanol for 1 min and rinse with transfer buffer;
    3. Install it in the order of "black edge of clip - sponge - filter paper - filter paper - glue -PVDF membrane - filter paper - filter paper - sponge - white edge of clip";
    4. The protein was electrotransferred to PVDF membrane. ( 0.45 µm PVDF membrane is recommended ) Reference Table for Selecting PVDF Membrane Pore Size Specifications
    Recommended conditions for wet transfer: 200 mA, 120 min.
    ( Note that the transfer conditions can be adjusted according to the protein size. For high-molecular-weight proteins, a higher current and longer transfer time are recommended. However, ensure that the transfer tank remains at a low temperature to prevent gel melting.)
     
    Block
    1. After electrotransfer, wash the film with TBST at room temperature for 5 minutes;
    2. Incubate the film in the blocking solution for 1 hour at room temperature;
    3. Wash the film with TBST for 3 times, 5 minutes each time.
     
    Antibody incubation
    1. Use 5% skim milk powder to prepare the primary antibody working liquid (recommended dilution ratio for primary antibody 1:1000), gently shake and incubate with the film at 4°C overnight;
    2. Wash the film with TBST 3 times, 5 minutes each time;
    3. Add the secondary antibody to the blocking solution and incubate with the film gently at room temperature for 1 hour;
    4. After incubation, wash the film with TBST 3 times for 5 minutes each time.
     
    Antibody staining
    1. Add the prepared ECL luminescent substrate (or select other color developing substrate according to the second antibody) and mix evenly;
    2. Incubate with the film for 1 minute, remove excess substrate (keep the film moist), wrap with plastic film, and expose in the imaging system.
    IF
    Experimental Protocol:
     
    Sample Preparation
    1. Adherent Cells: Place a clean, sterile coverslip in a culture dish. Once the cells grow to near confluence as a monolayer, remove the coverslip for further use.
    2. Suspension Cells: Seed the cells onto a clean, sterile slide coated with poly-L-lysine.
    3. Frozen Sections: Allow the slide to thaw at room temperature. Wash it with pure water or PBS for 2 times, 3 minutes each time.
    4. Paraffin Sections: Deparaffinization and rehydration. Wash the slide with pure water or PBS for 3 times, 3 minutes each time. Then perform antigen retrieval.
     
    Fixation
    1. Fix the cell coverslips/spots or tissue sections at room temperature using a fixative such as 4% paraformaldehyde (4% PFA) for 10-15 minutes.
    2. Wash the sample with PBS for 3 times, 3 minutes each time.
     
    Permeabilization
    1.Add a detergent such as 0.1–0.3% Triton X-100 to the sample and incubate at room temperature for 10–20 minutes.
    (Note: This step is only required for intracellular antigens. For antigens expressed on the cell membrane, this step is unnecessary.)
    Wash the sample with PBS for 3 times, 3 minutes each time.
     
    Blocking
    Add blocking solution and incubate at room temperature for at least 1 hour. (Common blocking solutions include: serum from the same source as the secondary antibody, BSA, or goat serum.)
    Note: Ensure the sample remains moist during and after the blocking step to prevent drying, which can lead to high background.
     
    Immunofluorescence Staining (Day 1)
    1. Remove the blocking solution and add the diluted primary antibody.
    2. Incubate the sample in a humidified chamber at 4°C overnight.
     
    Immunofluorescence Staining (Day 2)
    1. Remove the primary antibody and wash with PBST for 3 times, 5 minutes each time.
    2. Add the diluted fluorescent secondary antibody and incubate in the dark at 4°C for 1–2 hours.
    3. Remove the secondary antibody and wash with PBST for 3 times, 5 minutes each time.
    4. Add diluted DAPI and incubate at room temperature in the dark for 5–10 minutes.
    5. Wash with PBST for 3 times, 5 minutes each time.
     
    Mounting
    1. Mount the sample with an anti-fade mounting medium.
    2. Allow the slide to dry at room temperature overnight in the dark.
    3. Store the slide in a slide storage box at 4°C, protected from light.
     
    IHC
    Experimental Protocol:
     
    Deparaffinization/Rehydration
    1. Deparaffinize/hydrate sections:
    2. Incubate sections in three washes of xylene for 5 min each.
    3. Incubate sections in two washes of 100% ethanol for 10 min each.
    4. Incubate sections in two washes of 95% ethanol for 10 min each.
    5. Wash sections two times in dH2O for 5 min each.
    6.Antigen retrieval: For Citrate: Heat slides in a microwave submersed in 1X citrate unmasking solution until boiling is initiated; continue with 10 min at a sub-boiling temperature (95°-98°C). Cool slides on bench top for 30 min.
     
    Staining
    1. Wash sections in dH2O three times for 5 min each.
    2. Incubate sections in 3% hydrogen peroxide for 10 min.
    3. Wash sections in dH2O two times for 5 min each.
    4. Wash sections in wash buffer for 5 min.
    5. Block each section with 100–400 µl of blocking solution for 1 hr at room temperature.
    6. Remove blocking solution and add 100–400 µl primary antibody diluent in to each section. Incubate overnight at 4°C.
    7. Remove antibody solution and wash sections with wash buffer three times for 5 min each.
    8. Cover section with 1–3 drops HRPas needed. Incubate in a humidified chamber for 30 min at room temperature.
    9. Wash sections three times with wash buffer for 5 min each.
    10. Add DAB Chromogen Concentrate to DAB Diluent and mix well before use.
    11. Apply 100–400 µl DAB to each section and monitor closely. 1–10 min generally provides an acceptable staining intensity.
    12. Immerse slides in dH2O.
    13. If desired, counterstain sections with hematoxylin.
    14. Wash sections in dH2O two times for 5 min each.
    15. Dehydrate sections: Incubate sections in 95% ethanol two times for 10 sec each; Repeat in 100% ethanol, incubating sections two times for 10 sec each; Repeat in xylene, incubating sections two times for 10 sec each.
    16. Mount sections with coverslips and mounting medium.
     

    Datasheet & SDS

    生物学的記述

    Specificity
    p38β/MAPK11 + p38α/MAPK14 Antibody (Rabbit mAb) [M11B5] detects endogenous levels of total p38β/MAPK11 and p38α/MAPK14 protein.
    タンパク質の局在
    細胞質、細胞核
    Uniprot ID
    Q16539, Q15759
    Clone
    M11B5
    Synonym(s)
    CSBP, CSBP1, CSBP2, CSPB1, MXI2, SAPK2A, MAPK14, SAPK2a, PRKM11, SAPK2, SAPK2B, MAPK11, MAP kinase 11, MAPK 11, p38-2, MAP kinase p38 beta, p38b, SAPK2b
    Background
    p38α (MAPK14) and p38β (MAPK11) are closely related members of the p38 mitogen‑activated protein kinase subfamily within the wider MAPK family, sharing the conserved bilobal serine/threonine kinase fold with an activation loop containing the Thr‑Gly‑Tyr dual phosphorylation motif and acting as stress‑responsive kinases that integrate signals from upstream MAP3Ks and MAP2Ks to control transcriptional programs in immunity, inflammation and cancer. The catalytic cores of p38α and p38β are highly similar, but subtle differences in the activation loop, docking surfaces and C‑terminal tails confer isoform‑specific substrate preferences and regulatory interactions, with p38α generally more abundant and widely expressed and p38β showing distinct expression patterns in female tissue‑specific cancers and other contexts, where its levels can be reduced relative to normal tissue. Upon stimulation by cytokines, Toll‑like receptor agonists, bacterial antigens or other stressors, upstream MAP2Ks MKK3/MKK6 phosphorylate p38α and p38β, enabling these kinases to phosphorylate a range of substrates including transcription factors (ATF2, CREB, MEF2), chromatin regulators (MSK1/2) and other signaling proteins, and bioinformatic interactome analyses across 31 cancer types show that activation of p38 pathways is tightly linked to regulation of cell growth, differentiation, apoptosis and stress responses, with pathway activation levels correlating with both tumor progression and therapeutic responses. In macrophages and other immune cells, p38 activity modulates NF‑κB‑dependent inflammatory gene expression through at least two mechanisms: p38‑dependent phosphorylation and phosphoacetylation of histone H3 at promoters of selected cytokine and chemokine genes increases accessibility of cryptic κB sites and enhances NF‑κB recruitment, and p38–MSK1 signaling can phosphorylate RelA (p65) to boost NF‑κB transcriptional activation and tumor necrosis factor production in response to bacterial antigens. Pharmacologic inhibition of p38 using the selective inhibitor SB203580 attenuates lipopolysaccharide‑induced release of IL‑1β, IL‑6 and TNF‑α in alveolar epithelial models without blocking NF‑κB nuclear translocation, indicating that p38α/β are required for full expression of inflammatory cytokines downstream or parallel to NF‑κB, and tissue studies in crescentic glomerulonephritis show that phosphorylated p38 MAPK and activated NF‑κB co‑localize in crescentic lesions and tubular epithelium, correlate with chemokine (MIP‑1α) levels and inflammatory infiltrates, and decrease during glucocorticoid‑induced convalescence, linking p38–NF‑κB cross‑talk directly to human inflammatory kidney disease. In cancer, interactome‑based analyses reveal that p38α, p38β, p38γ and p38δ pathway activation has tumor‑type‑specific prognostic significance: high p38 pathway activation associates with poor survival in astrocytoma, glioblastoma, thymoma, renal, bladder, esophageal, colorectal, stomach cancers and lung squamous carcinoma, but correlates with better outcomes in HER2‑positive and luminal breast cancers, prostate carcinoma, sarcomas and lung adenocarcinoma, and p38β and p38γ activation in breast cancer is linked to positive responses to taxane and anthracycline therapies, whereas lower p38α/β activation predicts better responses to 5‑fluorouracil in colorectal cancer, highlighting that p38α/β signaling status can serve as a functional biomarker for therapy stratification and selective p38 inhibitor use.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください